<?xml version='1.0' encoding='utf-8'?>

<rss version="2.0">
  <channel>
    <title>The Federal Register</title>
    <link>http://thefederalregister.com/b.p/agency/Food_and_Drug_Administration/2006-11-22/</link>
    <description>Daily Publications of Meetings and Rules Changes for the Federal Government</description>
    <pubDate>Sat, Nov 22 2008 11:00:00 GMT</pubDate>
    <lastBuildDate>Sat, Nov 22 2008 11:00:00 GMT</lastBuildDate>
    <webMaster>info@thefederalregister.com</webMaster>
    <item>
  <title><![CDATA[  Guidance for Industry and Food and Drug Administration Staff;  Saline, Silicone Gel, and Alternative Breast Implants;]]></title>
  <link>http://thefederalregister.com/d.p/2006-11-22-06-9325</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is announcing the 
availability of the guidance entitled ``Saline, Silicone Gel, and 
Alternative Breast Implants.'' This version of the guidance document 
updates preclinical, clinical, and labeling recommendations described 
in ``Guidance for Saline, Silicone Gel, and Alternative Breast 
Implants,'' dated January 13, 2004. The update is based on the latest 
scientific and medical information on breast implants, and clarifies 
the type and amount of scientific data that should be submitted to 
allow FDA to evaluate whether these devices are safe and effective.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-11-22-06-9325</guid>
  <pubDate>Wed, Nov 22 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Draft Guidance for Industry on Sinusitis: Designing Clinical  Development Programs of Nonantimicrobial Drugs for]]></title>
  <link>http://thefederalregister.com/d.p/2006-11-22-E6-19689</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is announcing the 
availability of a draft guidance for industry entitled ``Sinusitis: 
Designing Clinical Development Programs of Nonantimicrobial Drugs for 
Treatment.'' Sinusitis is a common disease affecting an estimated 16 
percent of the adult U.S. population annually. At present, other than 
antimicrobials, the treatment options for sinusitis are limited. This 
guidance is intended to assist the pharmaceutical industry in designing 
clinical development programs for nonantimicrobial drug products for 
the treatment of sinusitis.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-11-22-E6-19689</guid>
  <pubDate>Wed, Nov 22 2006 11:00:00 GMT</pubDate>
</item>
</channel>
</rss>

